No Data
Chengdu Easton Biopharmaceuticals Co., Ltd. (SHSE:688513) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Yuandong Biology: Report for the third quarter of 2024
Chengdu Easton Biopharmaceuticals (688513.SH) released its performance for the first three quarters, with a net income of 0.217 billion yuan, a year-on-year increase of 12.03%.
Chengdu Easton Biopharmaceuticals (688513.SH) disclosed its third quarter report for 2024, achieving revenue of 10...
Chengdu Easton Biopharmaceuticals (688513.SH): The net income for the first three quarters was 0.217 billion yuan, a year-on-year increase of 12.03%.
Grain Du Hui October 24th | Chengdu Easton Biopharmaceuticals (688513.SH) announced its third-quarter report, with revenue of 1.04 billion yuan, a year-on-year increase of 22.38%, net income of 0.217 billion yuan, a year-on-year increase of 12.03%, non-GAAP net income of 0.168 billion yuan, a year-on-year increase of 14.92%, and basic earnings per share of 1.24 yuan.
These 4 Measures Indicate That Chengdu Easton Biopharmaceuticals (SHSE:688513) Is Using Debt Reasonably Well
US FDA Approves Easton Biopharma's Abbreviated New Drug Application for Anti-Hypertension Injection
Some Shareholders Feeling Restless Over Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) P/E RatioNo Data
No Data
